 |
Tamoxifen, Endoxifen in plasma by LC/MS (code LC92010) 100 test package. INSIGHTS Tamoxifen is an antitumor drug, belonging to the selective modulator class of estrogen receptors (SERM). The use of Tamoxifen is prescribed for breast cancer treatment and to prevent recurrence. In recent decades, Tamoxifen has been the most important therapeutic agent for the treatment of estrogen-receptor-positive breast cancers. Tamoxifen binds to the estrogen receptor by inhibiting the binding of estrogen and the subsequent proliferation of the tumor. The drug is metabolized in the liver from isoform CYP2D6 cytochrome P450, resulting in the formation of active metabolites, such as endoxifene and the 4-OH-tamoxifen. These molecules have the same binding affinity for the estrogen receptor ER-α and the same capacity to inhibit the proliferation of estrogen-dependent breast tumor cells that express this receptor. Principle of the Method: Tamoxifen and its primary active metabolite are analyzed by treating the plasma with a suitable reagent deproteinization. The solution is directly injected into the LC / MS. .
|
 |
back to previous page |
